Sikl's Department of Pathology, Faculty of Medicine, Charles University, E. Benese 13, 305 99, Pilsen, Czech Republic.
Bioptic Laboratory, Ltd, Pilsen, Czech Republic.
Virchows Arch. 2023 Oct;483(4):541-548. doi: 10.1007/s00428-023-03592-9. Epub 2023 Jul 4.
Branchioma (previously called ectopic hamartomatous thymoma, branchial anlage mixed tumor, or thymic anlage tumor) is a rare lower neck lesion with an adult male predominance and an uncertain histogenesis. Except for 4 cases, all branchiomas described in the literature were benign. Recently, HRAS mutation was detected in one case, but still little is known about the molecular genetic background of this rare entity. We herein report the histological, immunohistochemical, and molecular genetic analysis of a branchioma with a nested/organoid (neuroendocrine-like) morphology in a 78-year-old man. Histology revealed classical branchioma areas merging with nested/organoid cellular component lacking conventional features of malignancy. Immunohistochemistry was positive for high-molecular-weight cytokeratins. CD34 was expressed in the spindle cell component. Moreover, the tumor cells showed near-complete loss of retinoblastoma (RB1) expression (<1% of cells positive). All neuroendocrine markers (synaptophysin, chromogranin, and INSM1) were negative. Next-generation sequencing (TSO500 Panel) revealed 5 pathogenic/likely pathogenic mutations including 1 mutation in KRAS and 2 different mutations in each of MSH6 and PTEN. FISH and DNA sequencing were negative for RB1 gene alterations. To our knowledge, this is the first report of a branchioma showing misleading nested/organoid morphology and the first report on Rb1 immunodeficiency in this entity, in addition to multiple gene mutations revealed by NGS.
鳃裂瘤(以前称为异位错构性胸腺瘤、鳃裂原混合瘤或胸腺原肿瘤)是一种罕见的下颈部病变,以成年男性多见,其组织发生不确定。除了 4 例以外,文献中描述的所有鳃裂瘤均为良性。最近,在 1 例中检测到 HRAS 突变,但对于这种罕见实体的分子遗传学背景仍知之甚少。本文报道了 1 例 78 岁男性具有巢状/器官样(神经内分泌样)形态的鳃裂瘤的组织病理学、免疫组织化学和分子遗传学分析。组织学显示经典的鳃裂瘤区域与缺乏恶性常规特征的巢状/器官样细胞成分融合。免疫组织化学显示高分子量细胞角蛋白阳性。CD34 在梭形细胞成分中表达。此外,肿瘤细胞几乎完全丧失视网膜母细胞瘤(RB1)表达(<1%的细胞阳性)。所有神经内分泌标志物(突触素、嗜铬粒蛋白和 INSM1)均为阴性。下一代测序(TSO500 面板)显示 5 种致病性/可能致病性突变,包括 KRAS 中的 1 种突变和 MSH6 和 PTEN 中的每种 2 种不同突变。FISH 和 DNA 测序均为阴性,未发现 RB1 基因突变。据我们所知,这是首例报道具有误导性巢状/器官样形态的鳃裂瘤,也是首例报道该实体中 Rb1 免疫缺陷的病例,此外还通过 NGS 揭示了多种基因突变。